

# Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

## ICD-10 C66: Ureteral cancer

### Incidence and Mortality

Year of diagnosis	1998-2019
Patients	764
Diseases	775
Creation date	01/25/2021
Database export	01/07/2021
Population	4.92 m





Munich Cancer Registry  
Cancer Registry Bavaria - Upper Bavaria Regional Center  
at Klinikum Grosshadern/IBE  
Marchioninstr. 15  
Munich, 81377  
Germany

<https://www.tumorregister-muenchen.de/en>

[https://www.tumorregister-muenchen.de/en/facts/base/bC66\\_\\_E-ICD-10-C66-Ureteral-cancer-incidence-and-mortality.pdf](https://www.tumorregister-muenchen.de/en/facts/base/bC66__E-ICD-10-C66-Ureteral-cancer-incidence-and-mortality.pdf)

### Index of figures and tables

Fig./Tbl.		Page
1	Annual cases, DCO, mult. malignancies, follow-up / yr	4
2	Incidence by year of diagnosis	7
3	Age distribution parameters by year of diagnosis	8
4	Age distribution by 5-year age group and sex	11
5	Age-specific incidence, DCO rate, proportion malignancies	12
6	Age distribution and age-specific incidence (chart)	13
6a	Age-specific incidence internationally (chart)	14
7	Standardized incidence ratio of further malignancies	15
8a	Map of cancer incidence (BRD-S) by county (chart)	17
8b	Standardized incidence ratio (SIR) by county (chart)	18
9a	Pts incident cohorts and mortality / yr	19
9b	Incidence and mortality by year of diagnosis	20
9c	Cancer-related deaths, death certification available / yr	21
10	Medians of age at death / yr	22
11	Mortality by year of death	24
12	Distribution of age at death	26
13	Age-specific mortality	27
14	Further malignancies in deaths	28
15	Age-specific mortality (first primaries)	30
16	Age-specific mortality (single primaries)	31
17	Age distribution and age-specific mortality (chart)	32
18a	Map of cancer mortality (BRD-S) by county (chart)	33
18b	Standardized mortality ratio (SMR) by county (chart)	34

**Global Statements about the statistics on the Internet –  
Baseline Statistics** (grey button ) , **Survival** (red button )

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut<sup>#</sup>, with a total of 4.69 million inhabitants, account for the frequency of cancer diseases<sup>##</sup> and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases<sup>###</sup> are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to [tumor@ibe.med.uni-muenchen.de](mailto:tumor@ibe.med.uni-muenchen.de).

Munich Cancer Registry, January 2021

<sup>#</sup> Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.65 million to 4.10 in 2002, and to 4.69 million in 2007).

<sup>##</sup> Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.

<sup>###</sup> DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate.

### ICD-10 codes (ICD-10 2015) used for specifying cancer site

Code	Description
C66	Malignant neoplasm of ureter

## INCIDENCE

Table 1

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (ALL PATIENTS) (incl. DCO)

Year of diagnosis	All cases n	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	20			45.0	37.7	90.0	100.0
1999	10			46.7	36.6	90.0	100.0
2000	12			45.2	36.4	83.3	100.0
2001	24			42.4	36.0	95.8	100.0
2002	28			40.4	36.2	92.9	100.0 #
2003	19			38.9	36.3	73.7	100.0
2004	24			38.7	36.5	79.2	91.7
2005	42			40.8	35.7	73.8	90.5
2006	35			40.7	35.7	82.9	100.0
2007	36			41.2	34.8	77.8	100.0 #
2008	40			41.0	34.0	80.0	97.5
2009	45			41.5	32.9	75.6	97.8
2010	49	1	2.0	43.0	32.8	79.6	98.0
2011	47			45.9	30.6	66.0	100.0
2012	45	1	2.2	46.6	30.0	77.8	100.0
2013	54			47.2	29.0	72.2	100.0
2014	50			48.6	28.7	70.0	98.0
2015	32	1	3.1	49.3	27.1	59.4	100.0
2016	52			50.3	22.6	71.2	98.1
2017	42	1	2.4	51.3	21.6	38.1	100.0
2018	43			51.5	18.0	41.9	100.0
2019	26			51.6	13.6	15.4	73.1 ##
1998-2019	775	4	0.5	51.6	37.7	70.5	97.7

775 cases diagnosed 1998-2019 are related to a total of 764 patients. Currently, in 571 (74.7 %) of these 764 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 267 / 193 / 111 (34.9 % / 25.3 % / 14.5 %) patients exist having 2 / 3 / 4+ malignancies.

# The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2017, a subgroup of 42 cases has been diagnosed, of which 51.3 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 21.6 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1a

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (MALES) (incl. DCO)

Year of diagnosis	Males n	Males %	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	13	65.0			53.8	40.5	92.3	100.0
1999	6	60.0			52.6	39.0	83.3	100.0
2000	7	58.3			50.0	39.0	85.7	100.0
2001	13	54.2			48.7	38.6	92.3	100.0
2002	15	53.6			48.1	38.8	93.3	100.0 #
2003	10	52.6			48.4	38.7	90.0	100.0
2004	15	62.5			46.8	38.9	80.0	86.7
2005	30	71.4			47.7	37.7	76.7	90.0
2006	23	65.7			47.0	37.6	82.6	100.0
2007	28	77.8			46.9	37.1	78.6	100.0 #
2008	20	50.0			44.4	36.2	80.0	95.0
2009	30	66.7			45.7	34.3	70.0	96.7
2010	34	69.4			47.1	34.4	94.1	100.0
2011	27	57.4			49.8	31.0	77.8	100.0
2012	28	62.2			50.2	30.2	78.6	100.0
2013	28	51.9			50.5	29.3	78.6	100.0
2014	35	70.0			51.7	29.8	71.4	97.1
2015	21	65.6			52.0	29.1	47.6	100.0
2016	33	63.5			53.4	22.8	81.8	100.0
2017	30	71.4			54.5	20.3	40.0	100.0
2018	30	69.8			54.8	14.0	46.7	100.0
2019	18	69.2			54.5	13.3	22.2	61.1 ##
1998-2019	494	63.7			54.5	40.5	72.9	97.0

494 cases diagnosed 1998-2019 are related to a total of 485 patients. Currently, in 382 (78.8 %) of these 485 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 173 / 131 / 78 (35.7 % / 27.0 % / 16.1 %) patients exist having 2 / 3 / 4+ malignancies.

# The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2017, a subgroup of 30 cases has been diagnosed, of which 54.5 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 20.3 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1b

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (FEMALES) (incl. DCO)

Year of diagnosis	Females n	Females %	DCO cases n	Prop. DCO %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	7	35.0			28.6	32.7	85.7	100.0
1999	4	40.0			36.4	32.4	100.0	100.0
2000	5	41.7			37.5	32.0	80.0	100.0
2001	11	45.8			33.3	31.4	100.0	100.0
2002	13	46.4			30.0	31.6	92.3	100.0 #
2003	9	47.4			26.5	32.1	55.6	100.0
2004	9	37.5			27.6	32.0	77.8	100.0
2005	12	28.6			30.0	32.0	66.7	91.7
2006	12	34.3			30.5	32.3	83.3	100.0
2007	8	22.2			31.1	30.7	75.0	100.0 #
2008	20	50.0			35.5	30.2	80.0	100.0
2009	15	33.3			34.4	30.5	86.7	100.0
2010	15	30.6	1	6.7	35.7	29.9	46.7	93.3
2011	20	42.6			39.4	29.8	50.0	100.0
2012	17	37.8	1	5.9	40.7	29.5	76.5	100.0
2013	26	48.1			41.9	28.3	65.4	100.0
2014	15	30.0			43.6	26.5	66.7	100.0
2015	11	34.4	1	9.1	45.0	23.2	81.8	100.0
2016	19	36.5			45.2	22.2	52.6	94.7
2017	12	28.6	1	8.3	45.8	25.0	33.3	100.0
2018	13	30.2			45.8	27.8	30.8	100.0
2019	8	30.8			46.6	14.3		100.0 ##
1998-2019	281	36.3	4	1.4	46.6	32.7	66.2	98.9

281 cases diagnosed 1998-2019 are related to a total of 279 patients. Currently, in 189 (67.7 %) of these 279 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 94 / 62 / 33 (33.7 % / 22.2 % / 11.8 %) patients exist having 2 / 3 / 4+ malignancies.

# The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2017, a subgroup of 12 cases has been diagnosed, of which 45.8 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 25.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 2

Incidence measures by year of diagnosis including DCO cases  
(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,  
and from 4.10 to 4.92 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	13	7	1.2	0.6	0.8	0.3	1.1	0.4	1.5	0.5
1999	6	4	0.5	0.3	0.3	0.1	0.5	0.2	0.7	0.2
2000	7	5	0.6	0.4	0.4	0.2	0.6	0.2	0.8	0.4
2001	13	11	1.1	0.9	0.6	0.4	1.0	0.6	1.4	0.8
2002	15	13	0.8	0.7	0.4	0.3	0.7	0.5	0.9	0.6
2003	10	9	0.5	0.5	0.2	0.2	0.4	0.3	0.6	0.4
2004	15	9	0.8	0.5	0.4	0.2	0.6	0.3	0.9	0.4
2005	30	12	1.6	0.6	0.8	0.3	1.3	0.4	1.7	0.5
2006	23	12	1.2	0.6	0.6	0.2	0.9	0.3	1.2	0.5
2007	28	8	1.3	0.3	0.6	0.1	0.9	0.2	1.2	0.3
2008	20	20	0.9	0.9	0.5	0.3	0.7	0.5	0.9	0.7
2009	30	15	1.3	0.6	0.7	0.2	1.0	0.3	1.3	0.5
2010	34	15	1.5	0.6	0.6	0.3	1.0	0.5	1.5	0.6
2011	27	20	1.2	0.9	0.6	0.3	0.9	0.4	1.2	0.6
2012	28	17	1.2	0.7	0.5	0.2	0.8	0.4	1.2	0.6
2013	28	26	1.2	1.1	0.5	0.3	0.8	0.5	1.1	0.8
2014	35	15	1.5	0.6	0.6	0.2	1.0	0.4	1.4	0.5
2015	21	11	0.9	0.5	0.4	0.1	0.6	0.2	0.8	0.3
2016	33	19	1.4	0.8	0.6	0.3	0.9	0.5	1.3	0.6
2017	30	12	1.2	0.5	0.5	0.1	0.8	0.2	1.1	0.3
2018	30	13	1.2	0.5	0.6	0.1	0.8	0.2	1.1	0.4
2019	18	8	0.7	0.3	0.3	0.1	0.5	0.2	0.7	0.2
1998-2019	494	281	1.1	0.6	0.5	0.2	0.8	0.3	1.1	0.5

The computation of the incidence measures includes all cancers, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (ALL PATIENTS)  
(incl. DCO)

Year of diagnosis	Cases n	Std.		Min.	Max.	Median				
		Mean	dev.			10%	25%	50%	75%	90%
1998	20	70.4	9.0	49.0	83.3	57.1	66.9	70.0	78.3	81.1
1999	10	76.9	10.4	55.0	89.5	62.4	72.3	76.8	87.7	88.6
2000	12	71.2	10.4	45.2	81.7	62.8	66.7	73.1	79.8	80.6
2001	24	73.6	7.4	57.2	87.5	61.8	70.4	74.6	77.9	80.5
2002	28	70.6	9.8	51.7	91.1	58.2	62.5	72.1	75.6	85.0
2003	19	74.5	8.6	56.6	87.3	60.9	69.8	77.4	80.7	85.0
2004	24	72.8	11.4	46.3	94.6	54.9	69.6	74.2	79.8	84.2
2005	42	69.6	13.0	36.1	93.3	53.1	65.8	71.0	77.6	82.7
2006	35	73.0	9.4	50.5	88.7	59.2	67.0	73.4	80.4	84.6
2007	36	72.4	8.4	53.2	87.8	60.3	67.2	73.9	76.4	83.7
2008	40	72.4	9.5	49.3	87.2	61.5	64.5	73.5	79.8	84.5
2009	45	73.3	10.5	29.1	89.0	60.2	69.8	73.8	81.3	83.9
2010	49	73.7	8.9	52.4	92.7	60.0	69.7	73.8	80.4	84.6
2011	47	72.3	9.9	50.3	89.7	58.5	64.6	72.6	80.3	84.8
2012	45	75.2	10.0	49.0	92.8	61.7	68.5	77.4	82.4	83.9
2013	54	74.4	9.7	40.0	90.2	61.7	70.3	75.6	81.7	83.8
2014	50	73.6	10.4	45.1	90.8	59.5	68.0	75.3	80.4	87.6
2015	32	75.2	11.6	52.5	98.9	58.7	68.8	75.4	83.7	90.3
2016	52	73.8	11.0	43.9	94.1	60.3	66.7	75.7	81.5	87.1
2017	42	75.5	7.3	57.5	89.2	67.0	69.2	75.8	81.1	84.7
2018	43	74.6	9.7	51.5	93.4	62.1	65.8	77.4	80.4	87.9
2019	26	74.9	7.9	61.0	91.4	65.1	69.3	73.9	81.0	85.1
1998-2019	775	73.4	9.9	29.1	98.9	60.0	67.6	74.4	80.4	85.0



Table 3a

Age distribution parameters by year of diagnosis (MALES)  
(incl. DCO)

Year of diagnosis	Cases n	Std.		Min.	Max.	Median				
		Mean	dev.			10%	25%	50%	75%	90%
1998	13	69.5	9.1	49.0	81.7	55.6	67.8	69.9	74.9	80.4
1999	6	74.0	11.6	55.0	89.5	55.0	69.7	74.4	80.9	89.5
2000	7	68.9	11.5	45.2	80.3	45.2	66.2	73.0	76.6	80.3
2001	13	73.7	6.6	61.6	86.8	64.0	70.5	74.8	76.9	78.0
2002	15	70.1	9.9	52.0	91.1	58.2	62.3	71.4	75.3	80.3
2003	10	74.4	10.8	56.6	87.3	58.8	63.9	79.1	81.2	86.1
2004	15	73.4	9.8	54.9	86.9	55.9	69.8	74.9	80.1	84.2
2005	30	70.8	11.7	47.6	93.3	53.9	65.9	71.2	77.6	85.9
2006	23	71.4	8.0	50.5	84.3	64.0	65.8	71.2	79.7	80.5
2007	28	71.8	8.8	53.2	87.8	59.6	66.8	71.2	76.3	86.4
2008	20	70.0	10.9	49.3	87.2	55.0	62.5	70.3	78.8	85.0
2009	30	70.7	11.2	29.1	89.0	59.8	65.0	70.4	77.6	82.7
2010	34	76.3	7.6	60.0	92.7	67.4	70.4	76.8	82.1	85.1
2011	27	69.2	9.7	50.3	84.9	58.0	62.0	67.6	79.5	82.6
2012	28	73.0	9.9	49.0	89.1	57.4	67.4	75.1	81.8	83.4
2013	28	72.9	10.5	40.0	86.3	59.7	66.7	74.5	81.3	83.4
2014	35	74.2	11.1	45.1	90.8	57.3	68.2	75.9	81.2	88.1
2015	21	73.5	11.7	52.5	98.9	56.7	69.6	75.3	80.8	84.7
2016	33	74.8	9.9	49.9	94.1	62.7	69.8	76.9	81.3	86.4
2017	30	74.8	6.6	59.9	86.4	66.5	69.2	75.6	79.1	84.2
2018	30	72.9	10.3	51.5	93.4	61.4	64.4	73.4	79.0	88.4
2019	18	73.9	8.1	61.0	91.4	62.3	69.3	72.4	79.8	85.1
1998-2019	494	72.7	9.8	29.1	98.9	59.9	66.7	73.6	79.7	84.6

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)  
(incl. DCO)

Year of diagnosis	Cases n	Std.		Min.	Max.	Median				
		Mean	dev.			10%	25%	50%	75%	90%
1998	7	72.2	9.1	58.5	83.3	58.5	64.7	72.4	80.2	83.3
1999	4	81.2	7.8	72.3	87.8	72.3	74.6	82.3	87.7	87.8
2000	5	74.3	8.7	62.8	81.7	62.8	67.3	79.2	80.6	81.7
2001	11	73.5	8.6	57.2	87.5	61.8	70.4	73.7	79.9	80.5
2002	13	71.1	10.1	51.7	87.0	58.6	65.3	72.7	76.0	85.0
2003	9	74.6	6.0	64.1	83.1	64.1	71.0	75.0	79.2	83.1
2004	9	71.8	14.3	46.3	94.6	46.3	69.4	73.5	79.4	94.6
2005	12	66.5	15.9	36.1	91.0	38.2	62.4	69.4	75.9	78.2
2006	12	76.0	11.4	52.1	88.7	58.1	73.1	75.8	85.4	87.4
2007	8	74.7	6.8	60.3	82.8	60.3	72.6	75.7	78.8	82.8
2008	20	74.7	7.3	63.4	85.7	64.1	68.6	74.5	81.0	84.5
2009	15	78.7	6.4	66.0	87.2	67.9	74.3	80.6	83.9	84.0
2010	15	68.1	9.3	52.4	79.8	54.6	59.4	72.2	75.6	78.5
2011	20	76.4	8.9	56.8	89.7	63.4	71.5	76.6	84.1	87.3
2012	17	78.9	9.3	56.7	92.8	67.2	77.7	80.0	83.3	91.5
2013	26	76.0	8.7	52.6	90.2	61.7	72.5	77.9	81.7	84.8
2014	15	72.2	8.5	59.5	88.0	59.5	65.4	73.5	76.8	85.4
2015	11	78.3	11.3	59.5	91.9	66.5	68.1	77.7	90.3	90.4
2016	19	72.1	12.9	43.9	88.0	53.0	64.3	73.8	81.6	87.9
2017	12	77.4	8.9	57.5	89.2	68.1	71.3	80.4	82.7	86.2
2018	13	78.6	6.9	61.3	88.6	69.8	77.6	79.0	81.2	87.5
2019	8	77.3	7.5	66.8	87.4	66.8	71.0	77.9	83.1	87.4
1998-2019	281	74.7	9.9	36.1	94.6	60.3	69.2	75.7	81.2	86.7

Table 4

Age distribution by 5-year age group and sex for period 2007-2019  
(incl. DCO)


Age at diagnosis Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4									
5-9									
10-14									
15-19									
20-24									
25-29	1	0.2	0.2	1	0.3	0.3			0.0
30-34	0	0.0	0.2			0.3			0.0
35-39	1	0.2	0.4	1	0.3	0.6			0.0
40-44	1	0.2	0.5			0.6	1	0.5	0.5
45-49	4	0.7	1.2	4	1.1	1.7			0.5
50-54	16	2.9	4.1	11	3.0	4.7	5	2.5	3.0
55-59	25	4.5	8.6	15	4.1	8.8	10	5.0	8.0
60-64	51	9.1	17.6	40	11.0	19.9	11	5.5	13.6
65-69	83	14.8	32.4	59	16.3	36.2	24	12.1	25.6
70-74	98	17.5	49.9	66	18.2	54.4	32	16.1	41.7
75-79	120	21.4	71.3	72	19.9	74.3	48	24.1	65.8
80-84	102	18.2	89.5	59	16.3	90.6	43	21.6	87.4
85+	59	10.5	100.0	34	9.4	100.0	25	12.6	100.0
All ages	561	100.0		362	100.0		199	100.0	

Table 5


Age-specific incidence, DCO rate and proportion of all cancers for period 2007–2019

Age at diagnosis Years	Males n	Females n	Males Age- spec. incid. %	Females Age- spec. incid. %	Males DCO rate n=0 %	Females DCO rate n=4 %	Males Prop.all cancers n=143063 %	Females Prop.all cancers n=144724 %
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29	1		0.0				0.1	
30-34								
35-39	1		0.0				0.1	
40-44		1		0.0				0.0
45-49	4		0.2				0.1	
50-54	10	5	0.4	0.2			0.1	0.0
55-59	14	10	0.7	0.5			0.1	0.1
60-64	39	11	2.4	0.6			0.2	0.1
65-69	59	24	3.9	1.4			0.3	0.1
70-74	64	32	4.6	2.0			0.2	0.2
75-79	72	47	6.5	3.4		2.1	0.3	0.3
80-84	59	43	9.0	4.4		2.3	0.4	0.3
85+	34	25	8.0	2.6		8.0	0.3	0.2
All ages	357	198			0.0	2.0	0.2	0.1
Incidence								
Raw			1.2	0.6				
WS			0.5	0.2				
ES			0.8	0.3				
BRD-S			1.1	0.5				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).



**Figure 6.** Age distribution (males: mean=73.2 yrs, median=74.1 yrs; females: mean=75.5 yrs, median=76.8 yrs) and age-specific incidence.



**Figure 6a.** Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER\*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2019, based on the November 2018 submission. <http://www.seer.cancer.gov>.

Table 7a

Standardized incidence ratio (SIR, with 95% confidence limits),  
excess absolute risk (EAR) and DCO rate of further malignancies  
for period 1998-2019

## MALES

Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C12-C13 Hypopharynx	1	0.1	7.9	0.2	44.0	5.6	
C14 ENT cancer	1	0.0	118.0	3.0	657.3 #	6.4	
C15 Oesophagus	3	0.5	5.5	1.1	16.0 #	15.8	33.3
C16 Stomach	2	1.3	1.5	0.2	5.4	4.2	
C17 Small intestine	1	0.2	5.5	0.1	30.7	5.3	
C18 Colon	5	3.2	1.6	0.5	3.6	11.4	20.0
C19-C20 Rectum	2	1.6	1.3	0.2	4.6	2.8	
C22 Liver	2	0.9	2.3	0.3	8.3	7.2	
C25 Pancreas	2	1.3	1.6	0.2	5.7	4.7	100.0
C32 Larynx	1	0.3	3.8	0.1	21.2	4.7	
C33-C34 Lung	9	3.6	2.5	1.2	4.8 #	34.9	22.2
C43 Malign. melanoma	2	1.3	1.5	0.2	5.5	4.4	
C61 Prostate	36	8.5	4.2	3.0	5.9 #	176.7	2.8
C64 Kidney	12	1.0	12.0	6.2	20.9 #	70.7	50.0
C65 Renal pelvis	52	0.1	347.7	259.6	455.9 #	333.2	
C66 Ureter	9	0.1	99.7	45.6	189.3 #	57.3	
C67 Bladder	79	1.6	47.9	38.0	59.8 #	497.1	
C68 Urethra	8	0.0	250.3	108.0	493.1 #	51.2	
C68 Urinary org.	8	0.0	286.9	123.9	565.4 #	51.2	75.0
C76-C79 CUP	1	0.6	1.8	0.0	9.9	2.8	
C82-C85 NHL	1	1.4	0.7	0.0	4.1	-2.4	
C90 Mult. myeloma	2	0.4	4.7	0.6	17.0	10.1	50.0
Not observed	0	3.0	0.0	0.0	1.2	-19.4	
All further malignancies	239	31.1	7.7	6.7	8.7 #	1336	8.4
Patients		474					
Median age at next malignancy (years)		74.1					
Person-years		1556					
Mean observation time (years)		3.3					
Median observation time (years)		2.1					

# The occurrence of further specified malignancy is statistically significant.

Table 7b

Standardized incidence ratio (SIR, with 95% confidence limits),  
excess absolute risk (EAR) and DCO rate of further malignancies  
for period 1998–2019


## FEMALES

Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C16 Stomach	3	0.4	6.9	1.4	20.1 #	31.8	
C18 Colon	4	1.2	3.3	0.9	8.4	34.5	25.0
C23–C24 Bile	1	0.2	5.5	0.1	30.5	10.1	
C33–C34 Lung	5	0.8	6.3	2.0	14.7 #	52.1	
C50 Breast	5	3.0	1.7	0.5	3.9	25.1	
C54 Corpus uteri	2	0.6	3.4	0.4	12.4	17.6	
C56 Ovary	1	0.4	2.3	0.1	12.7	7.0	100.0
C64 Kidney	9	0.3	32.5	14.9	61.8 #	108.2	66.7
C65 Renal pelvis	22	0.0	561.8	352.1	850.6 #	272.3	
C66 Ureter	2	0.0	88.8	10.8	320.7 #	24.5	
C67 Bladder	35	0.3	138.9	96.7	193.2 #	430.8	2.9
C68 Urinary org.	1	0.0	183.7	4.7	1023 #	12.3	
C90 Mult. myeloma	1	0.2	6.6	0.2	37.0	10.5	
C91–C96 Leukaemia	1	0.2	5.6	0.1	31.1	10.2	
Not observed	0	3.5	0.0	0.0	1.1	-42.9	
All further malignancies	92	11.0	8.4	6.7	10.3 #	1004	9.8
Patients		273					
Median age at next malignancy (years)		77.3					
Person-years		807					
Mean observation time (years)		3.0					
Median observation time (years)		1.4					


# The occurrence of further specified malignancy is statistically significant.



Average incidence (Germany 1987 standard population) 2007 - 2019: Males




Average incidence (Germany 1987 standard population) 2007 - 2019: Females




**Figure 8a.** Map of cancer incidence (german standard population, incl. DCO cases) by county averaged for period 2007 to 2019. According to their individual incidence rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 1.1/100,000 WS N=357, females 0.5/100,000 WS N=198).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,462 female residents (averaged) in the period from 2007 to 2019 a total of 10 women were identified with newly diagnosed ureteral cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.9/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.4 and 2.1/100,000.

Standardized incidence ratio (SIR) 2007 - 2019: Males



Standardized incidence ratio (SIR) 2007 - 2019: Females



**Figure 8b.** Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2019. According to their individual SIR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=357, females N=198).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2019 a total of 10 women were identified with newly diagnosed ureteral cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 1.88. Though, the value of this parameter may vary with an underlying probability of 99% between 0.70 and 4.01, and is therefore not statistically striking.

## MORTALITY

Table 9a

Annual cohorts: Incident cancers, follow-up status, proportion of DCO, deaths among the annual cohorts and proportion of available death certificates (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.92 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Prop. DCO %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	20	100.0		18	90.0	100.0
1999	10	100.0		9	90.0	100.0
2000	12	100.0		10	83.3	100.0
2001	24	100.0		23	95.8	100.0
2002	28	100.0		26	92.9	96.2
2003	19	100.0		14	73.7	100.0
2004	24	91.7		19	79.2	89.5
2005	42	90.5		31	73.8	96.8
2006	35	100.0		29	82.9	96.6
2007	36	100.0		28	77.8	96.4
2008	40	97.5		32	80.0	93.8
2009	45	97.8		34	75.6	100.0
2010	49	98.0	2.0	39	79.6	100.0
2011	47	100.0		31	66.0	96.8
2012	45	100.0	2.2	35	77.8	88.6
2013	54	100.0		39	72.2	94.9
2014	50	98.0		35	70.0	82.9
2015	32	100.0	3.1	19	59.4	84.2
2016	52	98.1		37	71.2	75.7
2017	42	100.0	2.4	16	38.1	75.0
2018	43	100.0		18	41.9	55.6
2019	26	73.1		4	15.4	100.0
1998-2019	775	97.7	0.5	546	70.5	91.8

Table 9b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased within the same year of being diagnosed with cancer (incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.92 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	20	13	84.6	3	15.0
1999	10	8	100.0	1	10.0
2000	12	9	100.0	2	16.7
2001	24	12	100.0	3	12.5
2002	28	10	100.0	1	3.6
2003	19	24	95.8	3	15.8
2004	24	13	100.0	1	4.2
2005	42	16	100.0	4	9.5
2006	35	24	95.8	2	5.7
2007	36	20	95.0	1	2.8
2008	40	34	100.0	2	5.0
2009	45	31	100.0	7	15.6
2010	49	27	100.0	3	6.1
2011	47	45	97.8	7	14.9
2012	45	26	100.0	4	8.9
2013	54	31	100.0	9	16.7
2014	50	50	100.0	3	6.0
2015	32	51	96.1	3	9.4
2016	52	45	100.0	7	13.5
2017	42	47	93.6	7	16.7
2018	43	28	25.0	4	9.3
2019	26	34	58.8	2	7.7
1998–2019	775	598	92.3	79	10.2

Table 9c

Annual cohorts of deaths, proportion of cancer-related and non-cancer-related deaths, and cancer recorded on death certificates  
(incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,  
and from 4.10 to 4.92 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer- related %	Prop. non-cancer- related %	Prop. cancer recorded on death certificate %
1998	13	61.5	38.5	81.8
1999	8	75.0	25.0	87.5
2000	9	77.8	22.2	88.9
2001	12	75.0	25.0	83.3
2002	10	80.0	20.0	100.0
2003	24	87.5	12.5	87.0
2004	13	69.2	30.8	69.2
2005	16	81.3	18.8	81.3
2006	24	75.0	25.0	82.6
2007	20	85.0	15.0	94.7
2008	34	70.6	29.4	73.5
2009	31	83.9	16.1	90.3
2010	27	81.5	18.5	88.9
2011	45	80.0	20.0	88.6
2012	26	69.2	30.8	80.8
2013	31	71.0	29.0	83.9
2014	50	84.0	16.0	94.0
2015	51	64.7	35.3	73.5
2016	45	73.3	26.7	84.4
2017	47	78.7	21.3	86.4
2018	28	60.7	39.3	85.7
2019	34	50.0	50.0	80.0
1998–2019	598	74.1	25.9	84.6

Table 10a

Medians of age at death according to the grouping in Table 9  
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	4	65.2	66.6	61.3	66.6
1999	5	75.8	76.4	69.1	75.8
2000	6	71.8	67.0	71.8	70.6
2001	8	75.2	74.9	75.6	75.2
2002	6	74.6	73.4	78.8	74.6
2003	16	77.5	76.1	88.3	76.1
2004	7	75.6	74.6	94.7	74.6
2005	6	74.8	72.1	84.5	72.5
2006	15	78.8	77.6	82.0	78.2
2007	18	75.2	73.4	80.9	75.2
2008	20	76.8	75.9	79.7	76.1
2009	23	74.3	74.0	76.5	73.9
2010	16	75.8	75.2	78.1	75.8
2011	28	80.9	79.2	84.6	80.2
2012	19	77.3	75.8	79.3	77.3
2013	20	80.4	80.4	83.4	80.4
2014	28	79.0	79.0	85.3	79.0
2015	31	78.1	77.1	80.8	76.9
2016	31	78.6	77.9	91.9	78.5
2017	29	76.0	74.5	83.3	76.0
2018	22	76.1	68.4	83.9	69.9
2019	25	79.9	71.6	83.9	79.9
1998-2019	383	77.3	76.1	81.7	76.8

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 10b

Medians of age at death according to the grouping in Table 9  
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	9	78.0	67.4	84.8	72.7
1999	3	77.2	79.5	77.2	79.5
2000	3	73.2	73.2		73.2
2001	4	75.0	69.6	83.7	69.6
2002	4	73.6	73.6		73.6
2003	8	82.4	80.7	89.2	82.4
2004	6	78.3	80.3	76.2	80.3
2005	10	76.2	75.2	77.2	74.7
2006	9	83.1	84.8	79.0	80.0
2007	2	84.1	84.1		84.1
2008	14	79.5	78.6	84.9	79.5
2009	8	78.5	80.8	65.0	78.5
2010	11	77.6	77.3	78.8	77.3
2011	17	80.8	80.3	84.4	80.8
2012	7	83.3	76.2	83.9	79.8
2013	11	80.9	80.9	82.1	80.4
2014	22	81.4	76.1	87.7	80.2
2015	20	82.0	79.8	85.1	80.9
2016	14	84.3	78.9	90.4	80.1
2017	18	85.2	86.3	79.5	84.7
2018	6	88.4	85.0	93.8	86.4
2019	9	80.4	79.5	80.4	78.9
1998-2019	215	80.6	79.9	84.3	80.0

By 2018, Bavarians' life expectancy at birth is estimated at 79.3 years for boys and 83.8 years for girls.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11a

Mortality measures (cancer-related death) and mortality-incidence-index  
by year of death

MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	3	0.3	0.23	0.2	0.24	0.2	0.22	0.3	0.19
1999	4	0.4	0.67	0.2	0.55	0.3	0.62	0.6	0.76
2000	4	0.4	0.57	0.2	0.46	0.3	0.54	0.4	0.54
2001	7	0.6	0.54	0.3	0.54	0.5	0.53	0.8	0.57
2002	4	0.2	0.27	0.1	0.27	0.2	0.27	0.2	0.25
2003	14	0.7	1.40	0.4	1.43	0.6	1.46	0.9	1.46
2004	6	0.3	0.40	0.2	0.40	0.3	0.42	0.4	0.41
2005	4	0.2	0.13	0.1	0.13	0.2	0.13	0.2	0.12
2006	11	0.6	0.50	0.2	0.44	0.5	0.53	0.7	0.61
2007	15	0.7	0.56	0.3	0.56	0.5	0.59	0.7	0.62
2008	12	0.5	0.60	0.2	0.50	0.4	0.56	0.6	0.65
2009	19	0.9	0.63	0.4	0.55	0.6	0.60	0.8	0.62
2010	14	0.6	0.41	0.3	0.46	0.4	0.45	0.6	0.43
2011	22	1.0	0.85	0.4	0.61	0.6	0.73	0.9	0.81
2012	15	0.7	0.56	0.3	0.53	0.4	0.56	0.6	0.52
2013	15	0.7	0.54	0.3	0.51	0.4	0.55	0.6	0.55
2014	26	1.1	0.74	0.4	0.64	0.7	0.69	1.0	0.77
2015	21	0.9	1.05	0.3	0.94	0.5	1.00	0.8	1.04
2016	25	1.0	0.78	0.4	0.74	0.7	0.78	0.9	0.75
2017	25	1.0	0.83	0.4	0.91	0.7	0.86	0.9	0.86
2018	13	0.5	0.43	0.3	0.45	0.4	0.44	0.5	0.44
2019	13	0.5	0.72	0.3	0.74	0.4	0.73	0.5	0.71
1998-2019	292	0.7	0.60	0.3	0.56	0.5	0.59	0.7	0.61



Table 11b

Mortality measures (cancer-related death) and mortality-incidence-index  
by year of death  
FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	5	0.4	0.71	0.2	0.82	0.3	0.76	0.4	0.72
1999	2	0.2	0.50	0.1	0.66	0.1	0.62	0.2	0.72
2000	3	0.2	0.60	0.1	0.70	0.2	0.67	0.2	0.52
2001	2	0.2	0.18	0.1	0.18	0.1	0.17	0.1	0.18
2002	4	0.2	0.31	0.1	0.23	0.1	0.25	0.2	0.32
2003	7	0.4	0.78	0.1	0.67	0.2	0.67	0.2	0.64
2004	3	0.2	0.33	0.0	0.19	0.1	0.22	0.1	0.28
2005	9	0.5	0.75	0.2	0.54	0.3	0.61	0.3	0.67
2006	7	0.3	0.58	0.1	0.50	0.2	0.51	0.2	0.50
2007	2	0.1	0.25	0.0	0.11	0.0	0.14	0.1	0.19
2008	12	0.5	0.60	0.2	0.51	0.3	0.54	0.4	0.56
2009	7	0.3	0.47	0.1	0.46	0.1	0.46	0.2	0.39
2010	8	0.3	0.53	0.1	0.41	0.2	0.43	0.3	0.47
2011	14	0.6	0.70	0.1	0.51	0.3	0.58	0.4	0.70
2012	3	0.1	0.19	0.0	0.21	0.1	0.20	0.1	0.17
2013	7	0.3	0.27	0.1	0.21	0.1	0.22	0.2	0.25
2014	16	0.7	1.07	0.2	0.91	0.4	0.95	0.5	1.07
2015	12	0.5	1.09	0.2	1.10	0.3	1.08	0.4	1.21
2016	8	0.3	0.42	0.1	0.28	0.1	0.32	0.2	0.40
2017	12	0.5	1.00	0.1	0.73	0.2	0.81	0.3	0.83
2018	4	0.2	0.31	0.0	0.28	0.1	0.29	0.1	0.26
2019	4	0.2	0.50	0.0	0.45	0.1	0.47	0.1	0.47
1998-2019	151	0.3	0.54	0.1	0.46	0.2	0.48	0.2	0.50

Table 12

Age distribution of age at death (cancer-related) for period 2007-2019  
(incl. multiple malignancies)

Age at death Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4									
5-9									
10-14									
15-19									
20-24									
25-29									
30-34									
35-39									
40-44	1	0.3	0.3	1	0.4	0.4			0.0
45-49	0	0.0	0.3			0.4			0.0
50-54	8	2.3	2.6	6	2.6	3.0	2	1.8	1.8
55-59	10	2.9	5.5	8	3.4	6.4	2	1.8	3.7
60-64	22	6.4	11.9	19	8.1	14.5	3	2.8	6.4
65-69	40	11.6	23.5	29	12.3	26.8	11	10.1	16.5
70-74	54	15.7	39.2	39	16.6	43.4	15	13.8	30.3
75-79	65	18.9	58.1	45	19.1	62.6	20	18.3	48.6
80-84	76	22.1	80.2	45	19.1	81.7	31	28.4	77.1
85+	68	19.8	100.0	43	18.3	100.0	25	22.9	100.0
All ages	344	100.0		235	100.0		109	100.0	

Table 13

Age-specific mortality (cancer-related) and proportion of all cancers  
for period 2007-2019  
(incl. multiple malignancies)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	Males MI-index	Females Age- spec. mortal.	Females MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34								
35-39								
40-44	1		0.0	1.00			0.2	
45-49								
50-54	6	2	0.3	0.60	0.1	0.40	0.2	0.1
55-59	8	2	0.4	0.57	0.1	0.20	0.2	0.1
60-64	19	3	1.2	0.49	0.2	0.27	0.3	0.1
65-69	29	11	1.9	0.49	0.7	0.46	0.3	0.2
70-74	39	15	2.8	0.61	0.9	0.47	0.4	0.2
75-79	45	20	4.1	0.63	1.5	0.43	0.4	0.2
80-84	45	31	6.9	0.76	3.2	0.72	0.5	0.4
85+	43	25	10.1	1.26	2.6	1.00	0.5	0.2
All ages	235	109					0.4	0.2
Mortality								
Raw			0.8	0.66	0.4	0.55		
WS			0.3	0.61	0.1	0.46		
ES			0.5	0.64	0.2	0.48		
BRD-S			0.7	0.66	0.2	0.51		
PYLL-70								
per 100,000			1.7		0.4			
ES			1.4		0.3			
AYLL-70			7.1		6.1			

Table 14a

Further malignancies in deaths in period 1998-2019  
MALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C03-C06 Oral cavity	1	0.3	1	100.0				
C09-C10 Oropharynx	1	0.3	1	100.0				
C12-C13 Hypopharynx	2	0.6	1	50.0			1	50.0
C14 ENT cancer	1	0.3					1	100.0
C15 Oesophagus	4	1.2	1	25.0			3	75.0
C16 Stomach	3	0.9					3	100.0
C17 Small intestine	3	0.9	3	100.0				
C18 Colon	15	4.6	10	66.7	1	6.7	4	26.7
C19-C20 Rectum	7	2.1	4	57.1	1	14.3	2	28.6
C21 Anus/canal	1	0.3	1	100.0				
C22 Liver	1	0.3					1	100.0
C25 Pancreas	2	0.6					2	100.0
C32 Larynx	3	0.9	1	33.3	1	33.3	1	33.3
C33-C34 Lung	10	3.1	2	20.0	1	10.0	7	70.0
C43 Malign. melanoma	4	1.2	3	75.0			1	25.0
C44 Skin others	9	2.8	7	77.8			2	22.2
C46,C49 Soft tissue	2	0.6	2	100.0				
C61 Prostate	43	13.2	24	55.8	8	18.6	11	25.6
C62 Testis	2	0.6	2	100.0				
C64 Kidney	22	6.7	10	45.5	4	18.2	8	36.4
C65 Renal pelvis	41	12.6	7	17.1	26	63.4	8	19.5
C66 Ureter	14	4.3			5	35.7	9	64.3
C67 Bladder	107	32.8	48	44.9	15	14.0	44	41.1
C68 Urethra	7	2.1	2	28.6			5	71.4
C68 Urinary org.	10	3.1	1	10.0	3	30.0	6	60.0
C69 Eye melanoma	1	0.3	1	100.0				
C70-C72 CNS cancer	1	0.3					1	100.0
C76-C79 CUP	1	0.3	1	100.0				
C82-C85 NHL	7	2.1	5	71.4	2	28.6		
C90 Mult. myeloma	1	0.3					1	100.0
All further malignancies	326	100.0	138	42.3	67	20.6	121	37.1

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 14b

Further malignancies in deaths in period 1998-2019  
FEMALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C15 Oesophagus	1	0.6					1	100.0
C16 Stomach	3	1.9	1	33.3			2	66.7
C17 Small intestine	1	0.6	1	100.0				
C18 Colon	12	7.6	7	58.3	2	16.7	3	25.0
C19-C20 Rectum	4	2.5	3	75.0			1	25.0
C25 Pancreas	1	0.6	1	100.0				
C33-C34 Lung	6	3.8			2	33.3	4	66.7
C43 Malign. melanoma	4	2.5	4	100.0				
C44 Skin others	10	6.3	4	40.0			6	60.0
C48 Peritoneal	1	0.6	1	100.0				
C50 Breast	18	11.4	14	77.8			4	22.2
C53 Cervix uteri	7	4.4	7	100.0				
C54 Corpus uteri	5	3.2	5	100.0				
C56 Ovary	2	1.3	1	50.0			1	50.0
C64 Kidney	7	4.4	1	14.3	2	28.6	4	57.1
C65 Renal pelvis	22	13.9	4	18.2	11	50.0	7	31.8
C66 Ureter	4	2.5			1	25.0	3	75.0
C67 Bladder	41	25.9	14	34.1	3	7.3	24	58.5
C68 Urethra	1	0.6					1	100.0
C68 Urinary org.	3	1.9	1	33.3	1	33.3	1	33.3
C73 Thyroid	2	1.3	2	100.0				
C76-C79 CUP	1	0.6					1	100.0
C82-C85 NHL	2	1.3	2	100.0				
All further malignancies	158	100.0	73	46.2	22	13.9	63	39.9

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 15

Age-specific mortality (cancer-related) and proportion of all cancers  
for period 2007-2019  
(First primaries only \*)

Age at death Years	Males n	Females n	Males Age- spec. mortal. MI-index	Females Age- spec. mortal. MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4						
5- 9						
10-14						
15-19						
20-24						
25-29						
30-34						
35-39						
40-44						
45-49						
50-54	3	1	0.1	0.60	0.1	0.0
55-59	4	1	0.2	0.67	0.1	0.0
60-64	7	2	0.4	0.39	0.1	0.1
65-69	14	7	0.9	0.56	0.2	0.1
70-74	13	4	0.9	0.65	0.2	0.1
75-79	13	11	1.2	0.48	0.2	0.2
80-84	14	12	2.1	0.67	0.2	0.2
85+	15	13	3.5	2.50	0.3	0.1
All ages	83	51			0.2	0.1
Mortality						
Raw			0.3	0.63		
WS			0.1	0.59		
ES			0.2	0.62		
BRD-S			0.3	0.63		
PYLL-70						
per 100,000			0.7			0.2
ES			0.6			0.2
AYLL-70			6.8			5.7


\* See corresponding tables with multiple malignancies.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers  
for period 2007-2019  
(**Single primaries only** \*)

Age at death Years	Males n	Females n	Males Age- spec. mortal. MI-index	Females Age- spec. mortal. MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4						
5- 9						
10-14						
15-19						
20-24						
25-29						
30-34						
35-39						
40-44						
45-49						
50-54	2	1	0.1	0.67	0.1	0.0
55-59	2		0.1	0.50	0.1	
60-64	6	1	0.4	0.50	0.1	0.0
65-69	8	5	0.5	0.62	0.1	0.1
70-74	6	1	0.4	0.50	0.1	0.0
75-79	5	8	0.5	0.45	0.1	0.1
80-84	10	7	1.5	0.67	0.2	0.1
85+	6	7	1.4	2.00	0.1	0.1
All ages	45	30			0.1	0.1
Mortality						
Raw			0.1	0.60	0.1	0.54
WS			0.1	0.56	0.0	0.51
ES			0.1	0.59	0.0	0.51
BRD-S			0.1	0.60	0.1	0.52
PYLL-70						
per 100,000			0.5		0.1	
ES			0.4		0.1	
AYLL-70			6.9		5.4	

\* See corresponding tables with multiple malignancies.




**Figure 17.** Distribution of age at death (bars; males: mean=72.8 yrs, median=74.2 yrs; females: mean=75.6 yrs, median=77.6 yrs) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).


The difference between age at diagnosis (Table 3) and age at ureteral cancer-related death (see Table 10) should be considered.



Average mortality (Germany 1987 standard population) 2007 - 2019: Males




Average mortality (Germany 1987 standard population) 2007 - 2019: Females




**Figure 18a.** Map of cancer mortality (german standard population) by county averaged for period 2007 to 2019. According to their individual mortality rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 0.7/100,000 WS N=235, females 0.2/100,000 WS N=109).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,462 female residents (averaged) in the period from 2007 to 2019 a total of 5 women died from ureteral cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.5/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.1 and 1.4/100,000.

Standardized mortality ratio (SMR) 2007 - 2019: Males



Standardized mortality ratio (SMR) 2007 - 2019: Females



**Figure 18b.** Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2019. According to their individual SMR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=235, females N=109).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2019 a total of 5 women died from ureteral cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 1.73. Though, the value of this parameter may vary with an underlying probability of 99% between 0.37 and 4.89, and is therefore not statistically striking.

### Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases, where applicable. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

#### 1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

#### 2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

#### 3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head&neck and lung).

The ratio of mortality and incidence (mortality-to-incidence ratio, **MIR, MI-Index**) is a statistical index that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MIR. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

**Shortcuts**

MCR	Munich Cancer Registry (Tumorregister München)
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
SEER	Surveillance, Epidemiology, and End Results (USA)
DCO	Death certificate only
BRD-S	German (FRG) standard population
ES	European standard population (old)
WS	World standard population
SIR	Standardized incidence ratio
CI	Confidence interval
EAR	Excess absolute risk = excess cancer cases (O - E) per 10,000 person-years
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
SMR	Standardized mortality ratio
MI-index	Ratio of mortality to incidence, MIR
FRG	Federal Republic of Germany

**Recommended Citation**

Munich Cancer Registry. ICD-10 C66: Ureteral cancer - Incidence and Mortality [Internet]. 2021 [updated 2021 Jan 25; cited 2021 Mar 1]. Available from: [https://www.tumorregister-muenchen.de/en/facts/base/bC66\\_\\_E-ICD-10-C66-Ureteral-cancer-incidence-and-mortality.pdf](https://www.tumorregister-muenchen.de/en/facts/base/bC66__E-ICD-10-C66-Ureteral-cancer-incidence-and-mortality.pdf)

**Copyright**

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

**Disclaimer**

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.